Strategy Asset Managers’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Strategy Asset Managers's VRTX Position: Q2 2026 in Review
Strategy Asset Managers reduced its Vertex Pharmaceuticals (VRTX) stake by 3.3% in Q2 2026, selling an estimated $46.1K and leaving 3,060 shares worth $1.52M. The position accounts for 0.23% of the portfolio, ranked #83.
Strategy Asset Managers first reported a position in VRTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.59M in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Strategy Asset Managers held 3,060 shares of Vertex Pharmaceuticals worth $1.52M as of Q2 2026.
- Strategy Asset Managers sold 104 Vertex Pharmaceuticals shares in Q2 2026, an estimated $46.1K.
- Vertex Pharmaceuticals made up 0.23% of Strategy Asset Managers's portfolio in Q2 2026, its #83 holding.
- Strategy Asset Managers first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
- Strategy Asset Managers's Vertex Pharmaceuticals position peaked at $1.59M in Q2 2024.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Strategy Asset Managers's 13F filing for Q2 2026, filed 14 Aug 2026.